[
    [
        {
            "time": "",
            "original_text": "康泰生物上半年净利润同比下滑9.84% 拟募资30亿元 盈利能力下降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "净利润",
                    "同比下滑",
                    "募资",
                    "盈利能力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物上半年净利润同比下滑9.84% 拟募资30亿元 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物（300601）2019年中报点评：二季度环比改善，看好长期布局",
            "features": {
                "keywords": [
                    "康泰生物",
                    "中报",
                    "二季度",
                    "环比改善",
                    "长期布局"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物（300601）2019年中报点评：二季度环比改善，看好长期布局",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【天风医药】康泰生物：业绩短期下滑，13价肺炎疫苗等重磅品种值得期待 盈利能力下降",
            "features": {
                "keywords": [
                    "天风医药",
                    "康泰生物",
                    "业绩",
                    "短期下滑",
                    "13价肺炎疫苗",
                    "重磅品种"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【天风医药】康泰生物：业绩短期下滑，13价肺炎疫苗等重磅品种值得期待 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业海外医药2019H1定期报告总结之疫苗专题:重磅产品+中国市场,驱动国际疫苗销售明显提速",
            "features": {
                "keywords": [
                    "医药行业",
                    "海外医药",
                    "2019H1",
                    "疫苗",
                    "重磅产品",
                    "中国市场",
                    "国际疫苗销售",
                    "提速"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业海外医药2019H1定期报告总结之疫苗专题:重磅产品+中国市场,驱动国际疫苗销售明显提速",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "康泰生物:技术引进加自主研发,有望成为行业创新龙头",
            "features": {
                "keywords": [
                    "康泰生物",
                    "技术引进",
                    "自主研发",
                    "行业创新龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物:技术引进加自主研发,有望成为行业创新龙头",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]